First-Of-Kind Treatments Win Funding in England & Wales
NICE Fast-Tracks Novartis’s Beovu
Treatments for non-small cell lung cancer, Pompe disease and two main forms of ANCA-associated vasculitis from Roche, Sanofi and CSL Vifor respectively are to be made available for patients on the National Health Service.
You may also be interested in...
Roche’s Vabysmo is likely to be cost saving, according to NICE, which has also issued recommendations on the use of the drugs Oxlumo, Tavneos, Libtayo, Tepmetko and Ryeqo.
A parallel assessment mechanism that will allow new medicines in any therapeutic area to be considered for funding sooner is being introduced in New Zealand, where the new coalition government is working to repeal last year’s landmark Therapeutic Products Act.
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add three new products, including Velsipity, Pfizer's treatment for moderately to severely active ulcerative colitis in patients 16 years of age and older.